Cogent Biosciences, Inc. · NASDAQ:COGT
Cogent Biosciences — Unum Therapeutics — Cowen and Company 39th Annual Healthcare Conference 2019
28 slides from Cogent Biosciences's conference presentation, Mar 7, 2019
Slide 1: Unum Therapeutics Corporate Presentation
Exhibit 99.1 UNUM THERAPEUTICS CORPORATE PRESENTATION TH COWEN AND COMPANY 39 ANNUAL HEALTHCARE CONFERENCE BOSTON, MA MARCH 2019Exhibit 99.1 UNUM THERAPEUTICS CORPORATE PRESENTATION TH COWEN AND COMPANY 39 ANNUAL HEALTHCARE CONFERENCE BOSTON, MA MARCH 2019
Slide 2: Forward-Looking Statements and Risk Factors
FORWARD-LOOKING STATEMENTS AND RISK FACTORS This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materiall
Slide 3: Key Company Highlights
KEY COMPANY HIGHLIGHTS Providing potentially curative T cell therapies to treat a broad range of cancer patients NOVEL TECHNOLOGIES to overcome limitations of current T cell therapies 1 Potent ANTI-TUMOR ACTIVITY and ENCOURAGING SAFETY in lead program 2 Ability to address challenges in treating SOLI
Slide 4: Current Challenges for T Cell Therapies
CURRENT CHALLENGES FOR T CELL THERAPIES CAR-T therapy liabilities limit their use in broad patient populations n CRS and/or neurotoxicity are observed in the majority of patients who are treated Severe toxicities with currently approved CAR-T therapies, and can be severe or life-threatening associat
Slide 5: ACTR: Antibody-Coupled T Cell Receptor
ACTR: ANTIBODY-COUPLED T CELL RECEPTOR An engineered T cell receptor that uses tumor-targeting mAbs to direct attack Potential ACTR benefits tumor-specific antibody § The same universal T cell product can be ACTR antigen used in several different cancer indications n Potent anti-tumor activity with
Slide 6: BOXR: Bolt-On Chimeric Receptor
BOXR: BOLT-ON CHIMERIC RECEPTOR Designed to improve T cell function in solid tumor microenvironments Potential BOXR benefits chimeric receptor ‘bolt-on’ (ACTR or CAR) transgene § T cell function improved by expression of a immunosuppressive cells ‘bolt-on’ transgene (e.g., metabolic (Treg, MDSC) enz
Slide 7: Pipeline
PIPELINE Rapidly expanding pipeline in both hematologic and solid tumor cancers Product Candidate Indication Antibody Pre-Clinical Phase I Hematologic Cancers ACTR707 r/r CD20+ B cell NHL rituximab ATTCK-20-03 ACTR087 r/r CD20+ B cell NHL rituximab ATTCK-20-2 SEA-BCMA ACTR087 r/r Multiple Myeloma AT
Slide 8: Hematologic Cancers
HEMATOLOGIC CANCERSHEMATOLOGIC CANCERS
Slide 9: ACTR in Lymphoma
ACTR IN LYMPHOMA Provides proof-of-platform for the ACTR technology, demonstrating potential best-in-class product profile § Compelling profile demonstrated at early dose levels in two independent trials in r/r NHL § ATTCK-20-03: ACTR707 (CD28) (selected as program lead) § ATTCK-20-2: ACTR087 (41BB)
Slide 10: Testing ACTR707 in NHL
TESTING ACTR707 IN NHL Study Design and Objectives § Phase I, single arm trial testing escalating single doses of ACTR+ T cells in combination with rituximab § Patients pretreated with 3 days of lymphodepleting chemotherapy (fludarabine + cytarabine) 2 § Rituximab administered on the R-CHOP schedule
Slide 11: ACTR707 Tolerability in NHL
ACTR707 TOLERABILITY IN NHL No DLTs and no significant CRS or neurologic events in the first two dose levels Subjects with Serious Adverse Events (SAEs) Related to ACTR707 Preferred Term, n (%) Dose Level 1 (n=6) Dose Level 2 (n=3) Febrile neutropenia 1 (17) 1 (33) Pancytopenia 0 (0) 1 (33) Subjects
Slide 12: ACTR707 Anti-Tumor Activity in NHL
ACTR707 ANTI-TUMOR ACTIVITY IN NHL Potent antitumor activity including complete responses in initial cohorts Dose Level 1 § Six enrolled and treated subjects § Three subjects with complete responses; three with disease progression Dose Level 2 § Three enrolled and treated subjects § One subject with
Slide 13: CD19 CAR-T Benchmark in NHL
CD19 CAR-T BENCHMARK IN NHL Initial data indicates potential for a durable CR rate in line with approved CD19 CAR-T with an improved safety profile YESCARTA® KYMRIAH® (axicabtagene ciloleucel) (tisagenlecleucel) Indication r/r DLBCL, PMBCL, TFL r/r DLBCL N evaluable for response 101 68 OR rate 72% 5
Slide 14: Product Opportunity in NHL
PRODUCT OPPORTUNITY IN NHL Potential to address unmet medical need for under-served patient populations Comparable durable CR rate and reduced CRS/neurotox would enable several paths forward § Compete directly with approved CAR-Ts § Move more quickly into earlier lines of therapy § Expand into new p
Slide 15: ACTR in Multiple Myeloma
ACTR IN MULTIPLE MYELOMA Multiple mechanisms of action of ACTR in combination with SEA-BCMA enable a potentially more effective treatment compared to BCMA-targeting CAR-T APRIL signaling blockade 2 Potential differentiating characteristics myeloma cell APRIL BCMA § Despite high response rates, durab
Slide 16: Testing ACTR087 in Multiple Myeloma
TESTING ACTR087 IN MULTIPLE MYELOMA Promising safety profile through early dose cohorts supports further dose escalation Study Design and Objectives § Phase I, single arm trial testing escalating single doses of ACTR+ T cells in combination with escalating SEA-BCMA § Patients pretreated with 3 days
Slide 17: Solid Tumor Cancers
SOLID TUMOR CANCERSSOLID TUMOR CANCERS
Slide 18: ACTR + Trastuzumab in HER2+ Tumors
ACTR + TRASTUZUMAB IN HER2+ TUMORS First ACTR solid tumor program tumor cell lines normal tissue cells § Combination for the treatment of adult patients with (HER2 high) (HER2 low) relapsed/refractory advanced HER2+ cancers § Enrolling patients with HER2+ breast cancer, gastric cancers, and other HE
Slide 19: Testing ACTR707 in HER2+ Solid Tumors
TESTING ACTR707 IN HER2+ SOLID TUMORS Study Design & Objectives § Open label Phase I adaptive dose-escalating study to define optimal ACTR cell dose and antibody dose § Key eligibility: Advanced HER2 (3+) solid tumor malignancy. Must have received adequate prior therapy including HER2 directed thera
Slide 20: BOXR Discovery Engine
IL-2 PGE 2 Prolif IL-2 Adenosine Prolif IL-2 Kynurenine Prolif Prolif TGF-b Prolif BOXR DISCOVERY ENGINE Enables discovery of ACTR- and CAR-based BOXR candidates Score addressing specific mechanisms of immunosuppression BOXR Discovery Engine Translational Medicine Biologic Hypothesis ACTR parent Ide
Slide 21: BOXR1030: First BOXR Candidate
BOXR1030: FIRST BOXR CANDIDATE BOXR1030 is a GPC3 targeted CAR-T engineered for enhanced metabolism in the solid tumor microenvironment 20 Stringent xenograft models deplete TME glucose § Low glucose compromises T cell function, correlates with poor 15 patient outcomes in lung and liver cancers 10 §
Slide 22: Solid Tumor Preclinical Pipeline
SOLID TUMOR PRECLINICAL PIPELINE Multiple platform technologies (ACTR and BOXR) enable a broad pipeline tailored to particular targets and tumor types ACTR-targeted BOXR overcomes immune cell suppression MDSCs Tregs BOXR parent MDSCs Tregs Tumor Targeting Technology: Either ACTR BOXR parent 100 BOXR
Slide 23: Building for the Future
BUILDING FOR THE FUTUREBUILDING FOR THE FUTURE
Slide 24: Platform Enhances Commercialization Potential
PLATFORM ENHANCES COMMERCIALIZATION POTENTIAL Reduced Scalable Reliability Turn around Simplifying Patient COGS capacity time patient care access Closed automated CMO capacity 100% success Currently in line Improved safety Improved safety profile supports current with best practice profile enables s
Slide 25: Strong Financial Position
STRONG FINANCIAL POSITION Unum has a capital-efficient business model and significant funding through both financing and partnerships Finances § In April 2018, completed an IPO and concurrent private placement, raising $77M in gross proceeds § $154M raised since inception § Current cash balance of $
Slide 26: Upcoming Milestones
UPCOMING MILESTONES Multiple readouts across programs in 2019 NHL ACTR707 + rituximab ATTCK-20-03: dose escalation completed ATTCK-20-03: preliminary data from cohort expansion ACTR087 + rituximab ATTCK-20-2: confirm recommended Ph2 dose (study completion) Multiple Myeloma ACTR087 + SEA-BCMA ATTCK-1
Slide 27: Experienced Leadership
EXPERIENCED LEADERSHIP Chuck Wilson, PhD Novartis, Global Head of Strategic Alliances Archemix, Chief Technology Officer Chief Executive Officer Seth Ettenberg, PhD Novartis, Head of Oncology Biologics CuraGen, NCI Chief Scientific Officer Geoff Hodge Xcellerex, VP Process Development & Manufacturin
Slide 28: Key Company Highlights
28 KEY COMPANY HIGHLIGHTS NOVEL, UNIVERSAL ACTR platform for cancer cell therapy 1 Promising ANTI-TUMOR ACTIVITY and FAVORABLE TOLERABILITY PROFILE 2 BROAD PIPELINE with three current clinical stage programs growing to four by 2019 3 Ability to expand pipeline RAPIDLY and COST EFFECTIVELY 4 EXPERIEN
Unum Therapeutics — Cowen and Company 39th Annual Healthcare Conference 2019 on 6ix